Literature DB >> 8917989

Opportunist mycobacteria in England and Wales: 1982 to 1994.

K Lamden1, J M Watson, G Knerer, M J Ryan, P A Jenkins.   

Abstract

Three thousand and fifty-two infections with opportunist mycobacteria were reported to the PHLS Communicable Disease Surveillance Centre from 1982 to 1994. The commonest reported species was Mycobacterium avium-intracellulare (MAI), followed by M. kansasii and M. malmoense. The annual totals of opportunist mycobacteria increased steadily over this period, mostly, but not exclusively, due to an increase in reports of MAI associated with HIV infection. There were also increases in reports of MAI not associated with HIV infection, and in reports of M. malmoense. The increase in reports of opportunist mycobacteria was seen throughout England and Wales, but underreporting of MAI infection in the National Health Service Thames regions appears to have increased in recent years. Continued referral of isolates of opportunist mycobacteria to one of the PHLS regional centres for mycobacteriology or the Mycobacterium Reference Unit, and reporting to CDSC, is essential for the surveillance of these infections.

Entities:  

Mesh:

Year:  1996        PMID: 8917989

Source DB:  PubMed          Journal:  Commun Dis Rep CDR Rev        ISSN: 1350-9349


  13 in total

1.  Cervical abscess in an immunocompetent patient with Mycobacterium malmoense pulmonary disease.

Authors:  Joao N Duarte; Nuno Marques; Leonor Barroso; Isabel Ramos; Rosa Sá; David Sanz; Artur Ferreira; Saraiva da Cunha
Journal:  Oral Maxillofac Surg       Date:  2011-11-05

2.  Mycobacterium malmoense-specific nested PCR based on a conserved sequence detected in random amplified polymorphic DNA fingerprints.

Authors:  J Kauppinen; R Mäntyjärvi; M L Katila
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

3.  A new agent of mycobacterial lymphadenitis in children: Mycobacterium heidelbergense sp. nov.

Authors:  W H Haas; W R Butler; P Kirschner; B B Plikaytis; M B Coyle; B Amthor; A G Steigerwalt; D J Brenner; M Salfinger; J T Crawford; E C Böttger; H J Bremer
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

4.  The epidemiology of atypical mycobacterial diseases in northern England: a space-time clustering and Generalized Linear Modelling approach.

Authors:  S P Rushton; M Goodfellow; A G O'Donnell; J G Magee
Journal:  Epidemiol Infect       Date:  2006-11-03       Impact factor: 2.451

5.  Mycobacterium malmoense lymphadenitis in Spain: first two cases in immunocompetent patients.

Authors:  A I López-Calleja; M A Lezcano; S Samper; F de Juan; M J Revillo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-06-26       Impact factor: 3.267

6.  Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006.

Authors:  Jonathan E Moore; Michelle E Kruijshaar; L Peter Ormerod; Francis Drobniewski; Ibrahim Abubakar
Journal:  BMC Public Health       Date:  2010-10-15       Impact factor: 3.295

7.  Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003.

Authors:  L W Ding; C C Lai; L N Lee; P R Hsueh
Journal:  Epidemiol Infect       Date:  2006-02-22       Impact factor: 2.451

8.  Non-tuberculous mycobacteria in cystic fibrosis.

Authors:  J K Torrens; P Dawkins; S P Conway; E Moya
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

9.  Differentiation of Mycobacterium kansasii infection from Mycobacterium tuberculosis infection: comparison of clinical features, radiological appearance, and outcome.

Authors:  D Shitrit; R Priess; N Peled; G Bishara; D Shlomi; M R Kramer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10       Impact factor: 3.267

10.  Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria.

Authors:  R E Weir; P E M Fine; B Nazareth; S Floyd; G F Black; E King; C Stanley; L Bliss; K Branson; H M Dockrell
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.